<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">In 2015, Spain developed a National Strategy for HCV treatment and instituted widespread scale-up of HCV DAA therapies for individuals coinfected with HIV and HCV, the vast majority (&gt; 85%) with a reported history of injecting drug use, and the remainder MSM or unknown [
 <xref ref-type="bibr" rid="CR17">17</xref>]. PWID are the main group at risk for HCV infection in Spain, and the main group at risk for prevalent and incident HIV/HCV coinfection [
 <xref ref-type="bibr" rid="CR17">17</xref>–
 <xref ref-type="bibr" rid="CR19">19</xref>]. In 2015, a multicentre prospective observational cohort of HIV-infected patients with chronic HCV infection from 21 reference centers in Andalusia, Spain was established (HERACLES cohort). From 2015 to 2017, the HERACLES cohort was used to assess HCV treatment uptake and outcomes among HIV/HCV coinfected patients, since implementation of the Spanish National Strategy [
 <xref ref-type="bibr" rid="CR17">17</xref>, 
 <xref ref-type="bibr" rid="CR20">20</xref>]. As such, it provided important data with which to examine the potential impact of this treatment scale-up on HCV incidence among PLWH and the broader population.
</p>
